TrialCancer immunology, immunotherapy : CII2024

SAFFRON-104: a phase Ib/II study of sitravatinib alone or with tislelizumab in advanced hepatocellular carcinoma and gastric cancer/gastroesophageal junction cancer.

Jin Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.